Vicore Pharma Holding AB (publ) (STO:VICO)

Sweden flag Sweden · Delayed Price · Currency is SEK
11.08
+0.34 (3.17%)
Aug 22, 2025, 5:29 PM CET
3.17%
Market Cap2.60B
Revenue (ttm)7.74M
Net Income (ttm)-370.92M
Shares Out234.61M
EPS (ttm)-1.87
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,178,516
Average Volume989,953
Open10.68
Previous Close10.74
Day's Range9.40 - 11.24
52-Week Range6.09 - 16.23
Beta0.34
RSI60.28
Earnings DateAug 22, 2025

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol VICO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.